Wire · opportunities
Weekly Recap: Sevabertinib FDA approval and BAY 3670549 Ph II trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
Bayer's oncology drug sevabertinib received FDA accelerated first-line approval for HER2-mutant non-small cell lung cancer (NSCLC) following positive Phase 1/2 trial results; additionally, Bayer launched a Phase II global trial of BAY 3670549, a GIRK4 inhibitor for atrial fibrillation.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
The FDA's accelerated approval of sevabertinib opens the US market to new HER2-mutant NSCLC treatments, pushing you to act on faster market entry or partnerships. The start of the BAY 3670549 trial signals expanding cardiology drug opportunities that could reshape atrial fibrillation care.
◆ Coverage
1 source · 14 Sep 2026
◆ Related on Wire
◆ Topics